Write in a clean editor, then format for Clinical Research in Cardiology Supplements in one click — DocuGuru applies the official Springer Nature template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Clinical Research in Cardiology Supplements is a peer-reviewed journal published by Springer Nature, covering Lipoproteins and Cardiovascular Health, Antiplatelet Therapy and Cardiovascular Diseases, Cardiac Imaging and Diagnostics.
| Publisher | Springer Nature |
|---|---|
| Reference style | Numbered (Springer Basic) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C (2023) A representative article title. Clinical Research in Cardiology Supplements 12:45–58
Formats any DOI in Clinical Research in Cardiology Supplements style. No sign-up. |
| Publishes research in | Lipoproteins and Cardiovascular Health Antiplatelet Therapy and Cardiovascular Diseases Cardiac Imaging and Diagnostics Atrial Fibrillation Management and Outcomes Acute Myocardial Infarction Research |
| ISSN | 1861-0706 |
| h-index | 19 |
| i10-index | 29 |
| Total citations | 1,336 |
| Article processing charge | $2,990 |
| Top institutions publishing here | Deutsches Herzzentrum der Charité |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Lipoprotein (a) (Lp(a)) is a modified low-density lipoprotein (LDL) particle with an additional specific apolipoprotein (a), covalently attached to apolipoprotein B‑100 of LDL by a single thioester bond. Increased plasma Lp(a) level is a genetically determined, independent, causal risk factor for cardiovascular disease.The precise quantification of Lp(a) in plasma is still hampered by mass-sensitive assays,…
Hypertriglyceridemia is associated with a number of severe diseases such as acute pancreatitis and coronary artery disease. In severe hypertriglyceridemia (SHTG, triglycerides > 1,000 mg/dL), rapid lowering of plasma triglycerides (TG) has to be achieved. Treatment regimes include nutritional intervention, the use of antihyperlipidemic drugs, and therapeutic apheresis. Apheretic treatment is indicated in medical emergencies…
Ischemic heart disease is the main cause of death worldwide and it is accelerated by increased low-density lipoprotein (LDL) cholesterol (LDL-C) and/or lipoprotein (a) (Lp(a)) concentrations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) alters both LDL-C and in part Lp(a) concentrations through its ability to induce degradation of the LDL receptor (LDLR). PCSK9, however, has additional…
